We aim to further investigate the safety, pharmacokinetics (PK) as well as anti-tumor activity of PRT3789 in the ongoing clinical trial (NCT05639751).Koichi ItoMichael HulseAnjana AgarwalJack CarterMonisha SivakumarKomali VykuntamMin WangMiles Cowart...
603O First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutationdoi:10.1016/j.annonc.2024.08.670R. GuoA. DowlatiI. Dagogo-Jack